• 1
    Bytzer P, Talley NJ, Leemon M, et al. Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults. Arch Intern Med 2001; 161(16): 198996.
  • 2
    Horowitz M, Fraser RJL. Gastroparesis: diagnosis and management. Scand J Gastroenterol 1995; 30(Suppl.): 716.
  • 3
    Frank L, Kleinman L, Ganoczy D, et al. Upper gastrointestinal symptoms in North America. Prevalence and relationship to healthcare utilization and quality of life. Dig Dis Sci 2000; 45: 80918.
  • 4
    Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997; 92: 97680.
  • 5
    Horowitz M, Wishart JM, Jones KL, et al. Gastric emptying in diabetes: an overview. Diabetes Med 1996; 13(9 Suppl. 5): S1622.
  • 6
    Leidy NK, Farup C, Rentz AM, Ganoczy D, Koch KL. Patient-based assessment in dyspepsia: development and validation of Dyspepsia Symptom Severity Index (DSSI). Dig Dis Sci 2000; 45: 11729.
  • 7
    Moyer CA, Fendrick AM. Measuring health-related quality of life in patients with upper gastrointestinal disease. Dig Dis 1998; 16: 31524.
  • 8
    Rabeneck L, Cook KF, Wristers K, Souchek J, Menke T, Wray NP. SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol 2001; 54: 75565.
  • 9
    Rentz AM, Battista C, Trudeau E, et al. Symptom and health-related quality of life measures for use in selected gastrointestinal disease studies: a review and synthesis of the literature. Pharmacoeconomics 2001; 19: 34963.
  • 10
    Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJC. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985; 30: 19.
  • 11
    Jones KL, Wishart JM, Berry MK, et al. Effects of fedotozine on gastric emptying and upper gastrointestinal symptoms in diabetic gastroparesis. Aliment Pharmacol Ther 2000; 14: 93743.
  • 12
    Silvers D, Kipnes M, Broadstone V, et al. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, tolerability, and quality of life outcomes in a multicenter controlled trial. Clin Ther 1998; 20: 43853.
  • 13
    Farup CE, Leidy NK, Murray M, et al. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998; 21: 1699706.
  • 14
    Koch KL, Stern RM, Stewart WR, et al. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone therapy. Am J Gastroenterol 1989; 84: 106975.
  • 15
    Patterson D, Abell T, Rothstein R, et al. A double-blind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999; 94: 12304.
  • 16
    Talley NJ, Verlinden M, Greenen DJ, et al. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double blind, placebo controlled trial. Gut 2001; 49: 395401.
  • 17
    Rentz AM, Schmier J, De La Loge C, et al. Development and preliminary psychometric validation of the patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM) in GI patients. In: Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research, Antwerp, Belgium, November 2000.
  • 18
    Schmier J, Rentz AM, De La Loge C, et al. Development and preliminary psychometric validation of the patient assessment of upper gastrointestinal disorders-symptom severity index (PAGI-SYM) in gastroparesis. In: Annual Meeting of the International. Society for Pharmacoeconomics and Outcomes Research, Antwerp, Belgium, November 2000.
  • 19
    Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center, 1993.
  • 20
    Jaeschke R, Singer J, Guyatt GH. Measurements of health status: ascertaining the minimal clinically important difference. Contr Clin Trials 1989; 10: 40715.
  • 21
    Guyatt GH, Osoba D, Wu AW, Wyrwich KW, Norman GR. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002; 77: 37183.
  • 22
    Revicki DA, Sorensen S, Maton PN, Orlando RC. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease. Dig Dis 1998; 16: 28491.
  • 23
    Guyatt GH, Juniper EF, Walter SF, Griffith LE, Goldstein RS. Interpreting treatment effects in randomized trials. Br Med J 1998; 316: 6903.
  • 24
    Juniper EF, Guyatt GH, Willian A, Griffith LE. Determining a minimal important change in a disease-specific quality of life questionnaire. J Clin Epidemiol 1994; 47: 817.
  • 25
    Ware JE Jr, Kosinski M, Keller SD. SF-36 Physical and Mental Health Summary Scales: A User's Manual. Boston, MA: The Health Institute, New England Medical Center, 1994.
  • 26
    Bityutskiy JP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis — clinical characteristics and long-term outcomes. Am J Gastroenterol 1997; 92(9): 15014.
  • 27
    Broadhead WE, Blazer DG, George LK, Tse CK. Depression, disability days, and days lost from work in a prospective epidemiologic survey. J Am Med Assoc 1990; 264: 25248.
  • 28
    Revicki DA, Irwin D, Reblando J, Simon GE. The accuracy of self-reported disability days. Med Care 1994; 32: 4014.
  • 29
    Hays RD, Anderson RT, Revicki DA. Assessing reliability and validity of measurement in clinical trials. In: StaquetMJ, HaysRD, FayersPM, eds. Quality of Life Assessment in Clinical Trials: Methods and Practice. Oxford: Oxford University Press, 1998.
  • 30
    Nunnally JC, Bernstein IH. Psychometric Theory, 3rd edn. New York: McGraw-Hill, 1994.
  • 31
    Coulie B, Camilleri M, Dubois D and the US Upper GI Epi Study Group. Symptoms suggestive of pathophysiological disturbances provide a basis for novel classification of functional upper gastrointestinal disorders. Poster presented at Digestive Diseases Week Annual Conference, San Francisco, May 2002.
  • 32
    Chassany O, Sagnier P, Marquis P, Fullerton S, Aaronson N, for the European Regulatory Issues on Quality of Life Assessment Group. Patient-reported outcomes: the example of health-related quality of life — a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Information J 2002; 36: 20918.
  • 33
    Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health 1999; 2: 11327.
  • 34
    Revicki DA, Osoba D, Fairclough D, et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual Life Res 2000; 9: 887900.